The ROI of Custom Healthcare Software: A CFO's Framework for Build vs. Buy Decisions

Every healthcare CFO eventually sits across from a vendor pitch and a build proposal for the same problem, and the numbers rarely make the decision obvious on their own. SaaS pricing looks cheaper until you model five years of per-provider licensing at scale. Custom development looks expensive until you account for what an off-the-shelf platform cannot do — and what that inability costs in clinical workarounds, denied claims, or compliance exposure. This is a financial framework for making that decision with real numbers instead of vendor talking points, written for CFOs and finance leaders who are increasingly the actual decision-makers on healthcare technology investment.

Table of Contents

• Why This Decision Has Moved to Finance
• The Real Cost Structure of Off-the-Shelf Healthcare Software
• The Real Cost Structure of Custom Development
• Modeling Total Cost of Ownership Over 5 Years
• Quantifying the Cost of Workarounds
• Risk-Adjusted ROI: Compliance and Vendor Lock-In
• A Decision Framework You Can Actually Use
• How Halkwinds Supports This Analysis
• FAQs

Key Takeaways

• Per-provider SaaS pricing that looks favorable at pilot scale frequently becomes the more expensive option once an organization crosses 150–250 licensed users, which is earlier than most finance teams model
• The largest hidden cost in off-the-shelf healthcare software is not the license — it is the fully-loaded cost of clinical and administrative staff time spent on manual workarounds for gaps between the software and actual workflow
• Custom software shifts cost from opex (subscription) to a mix of capex (initial build) and a smaller ongoing opex (maintenance), which materially changes both the P&L profile and the NPV calculation over a 5-year horizon
• Vendor lock-in and data portability risk should be modeled as a quantified financial risk (cost and time to migrate away, contractual exit terms), not treated as a qualitative concern

Why This Decision Has Moved to Finance

Ten years ago, build-versus-buy for healthcare software was primarily an IT decision informed by finance. Today it is frequently the reverse: healthcare organizations are managing tighter margins, value-based care contracts that reward operational efficiency, and increasing scrutiny on technology spend from boards and investors. CFOs are being asked to sign off on multi-year SaaS commitments with escalating per-seat pricing, and are increasingly the ones asking whether a custom-built alternative would actually be cheaper over the contract's full term — not just at signing.

The Real Cost Structure of Off-the-Shelf Healthcare Software

Off-the-shelf and SaaS healthcare platforms typically carry four cost components that are not always visible in the initial proposal: the base subscription (usually per provider, per bed, or per transaction), implementation and configuration fees (frequently 20–40% of first-year subscription cost), annual price escalators (commonly 5–12% year over year, sometimes tied to CPI, sometimes not), and integration fees for connecting the platform to your EHR, billing system, or data warehouse — which vendors often price per-interface and per-year. A platform quoted at $18 per provider per month can reasonably land at $30–40 per provider per month by year three once escalators and integration maintenance are included.

The Real Cost Structure of Custom Development

Custom development cost structure looks different in shape, not necessarily in total: a larger upfront investment (design, engineering, clinical workflow validation, security and compliance architecture), followed by a materially smaller ongoing cost — typically 15–25% of the initial build cost annually for maintenance, hosting, and incremental feature work, versus the 100%+ of first-year cost that SaaS subscriptions represent every single year. The financial profile is closer to a capital asset than a recurring expense, which is exactly why it needs to be modeled with NPV and payback period, not compared to SaaS on a simple annual-cost basis.

Modeling Total Cost of Ownership Over 5 Years

A defensible TCO model needs, at minimum: Year 0 build or implementation cost, Years 1–5 subscription or maintenance cost (with realistic escalators applied, not flat), integration and interface costs for both paths, a staff time cost for administering and configuring the system annually, and a terminal value or replacement cost assumption at year 5 (does the SaaS contract renew at the same structure, does the custom system need a re-architecture). Discounting these cash flows at your organization's actual cost of capital, rather than comparing undiscounted totals, is what separates a real financial analysis from a spreadsheet built to justify a decision that was already made.

Quantifying the Cost of Workarounds

This is the component most build-versus-buy analyses skip entirely, and it is frequently the largest number in the model. When an off-the-shelf platform does not fit a specific clinical workflow, staff do not stop working — they build a workaround: a shadow spreadsheet, a duplicate data entry step, a manual reconciliation process, a phone call that should have been an API call. Quantifying this requires estimating the fully-loaded hourly cost of the staff performing the workaround (salary, benefits, overhead — typically 1.3–1.5x base salary) multiplied by the time spent per instance multiplied by instance volume. A workaround that costs a clinical coordinator fifteen minutes per patient encounter, across a service line handling 200 encounters a week, is a real six-figure annual cost that a per-seat license comparison will never surface.

Risk-Adjusted ROI: Compliance and Vendor Lock-In

Two risk factors belong in the model as quantified numbers, not footnotes. First, compliance risk: does the off-the-shelf platform's data handling, audit logging, and BAA terms actually meet your organization's HIPAA and state privacy obligations, and what is the realistic cost of a gap (breach notification, remediation, potential penalties)? Second, vendor lock-in: what does it actually cost, in dollars and clinical disruption time, to migrate off this platform if pricing or terms become unfavorable in year three? Data export terms, API access for your own data, and contractual notice periods should all factor into a lock-in risk score that adjusts the effective cost of the SaaS option upward.

A Decision Framework You Can Actually Use

In practice, custom development tends to be the financially stronger choice when: the organization's provider count is large enough that per-seat SaaS costs compound significantly over 5 years, the required workflow is core to competitive differentiation rather than commodity administrative function, or workaround costs from an ill-fitting off-the-shelf platform are already measurable and significant. SaaS remains the stronger choice for genuinely commodity functions (standard scheduling, common administrative workflows) where switching cost and implementation speed outweigh long-run cost, and for organizations below the scale where custom development's fixed costs can be justified. The framework is not "custom is always cheaper" — it is "model both honestly, including the costs vendors do not put in the proposal."

How Halkwinds Supports This Analysis

We build the TCO and workaround-cost models alongside finance teams before any development commitment is made, using your actual provider counts, current vendor contracts, and observed workaround patterns rather than industry averages. Our build vs. buy comparison and healthcare app development cost guide go deeper into specific cost ranges. For the vendor-evaluation side of this same decision, see our guide on what to look for in a healthcare software development company, and for the operational upside a custom system can unlock, see how AI is transforming healthcare operations. If you are evaluating a build decision and want a financial model built on your organization's real numbers, contact us for a scoping conversation.

Frequently Asked Questions

At what scale does custom development typically become cheaper than SaaS?

There is no universal number, but in our experience modeling this across mid-size and enterprise health organizations, the crossover point commonly falls between 150 and 400 licensed users over a 5-year horizon, depending on the SaaS platform's per-seat pricing and escalator structure. Below that range, SaaS implementation speed usually outweighs the long-run cost advantage of custom development.

How do we account for the risk that a custom build runs over budget or timeline?

Risk-adjust the build estimate using a contingency factor based on the vendor's track record and the project's complexity — 15–25% contingency is typical for well-scoped healthcare software projects with an experienced team, higher for projects with significant undefined clinical workflow requirements. This contingency should be built into the Year 0 cost in the TCO model, not treated as a separate risk discussion.

Does this framework apply to point solutions as well as core clinical systems?

Yes, though the answer skews toward SaaS more often for point solutions — a narrow, well-defined administrative function is less likely to accumulate the workaround costs and differentiation value that tip the analysis toward custom development. The framework is most decision-relevant for systems that touch core clinical or revenue-cycle workflows.

Should we include the cost of hiring an in-house team to maintain custom software?

Only if you are planning to bring maintenance in-house. Most organizations that build custom healthcare software maintain it through the development partner or a hybrid model, in which case the maintenance cost is contractual and should be modeled as a fee, not an internal headcount cost. If in-house maintenance is the actual plan, fully-loaded headcount cost (including backfill risk for specialized healthcare engineering talent) needs to be in the model.

What discount rate should we use for the NPV calculation?

Use your organization's actual weighted average cost of capital or the hurdle rate finance already applies to capital projects of similar risk profile. Healthcare organizations commonly use rates in the 6–10% range for internal technology investment, but this should come from your finance team's standard capital budgeting practice, not a generic industry figure.